Cargando…
Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer
With approximately 240,890 new cases expected in 2011, prostate cancer remains the leading cause of non-melanoma cancer deaths in men. Immunotherapies using viral vector-based delivery systems targeting tumor-specific antigens are being studied. Viral vector-based delivery systems present tumor-targ...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256982/ https://www.ncbi.nlm.nih.gov/pubmed/22253556 http://dx.doi.org/10.4137/CMO.S7654 |